Business

Celldex Therapeutics Announces Pricing of Upsized $250 Million Public Offering of Common Stock |

HAMPTON, N.J., July 13, 2021 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (“Celldex” or the “Firm”) (Nasdaq: CLDX) as we speak introduced the pricing of an underwritten public providing of 5,952,381 shares of its frequent inventory at a public providing value of $42.00 per share. In reference to the providing, Celldex has granted the underwriters a 30-day choice to buy as much as a further 892,857 shares of frequent inventory on the public providing value, much less underwriting reductions and commissions.

Jefferies, SVB Leerink, Guggenheim Securities and Cantor are appearing because the joint book-running managers for the providing. LifeSci Capital LLC and H.C. Wainwright & Co. are appearing as co-lead managers for the providing.

The Firm expects to obtain gross proceeds from the providing, excluding the train of the underwriters’ choice, if any, of roughly $250 million, excluding underwriting reductions and commissions and different offering-related bills.

Celldex intends to make use of the web proceeds from the providing to proceed medical and preclinical improvement of its product candidates, together with present and future improvement of CDX-0159, rising its bispecific antibody platform and medical candidates, funding ongoing efforts to develop extra medical pipeline merchandise and for common company functions.

The providing is predicted to shut on July 16, 2021, topic to customary closing situations.

The securities described above are being provided pursuant to a prospectus complement and an accompanying base prospectus forming a part of a shelf registration assertion on Type S-3 (File No. 333-249917), which was beforehand filed with the Securities and Change Fee (“SEC”) and deemed efficient on November 6, 2020. A last prospectus complement regarding the providing might be filed with the SEC and might be out there on the SEC’s web site situated at http://www.sec.gov. When out there, copies of the ultimate prospectus complement and the accompanying base prospectus could also be obtained free of charge by contacting Jefferies LLC, Consideration: Fairness Syndicate Prospectus Division, 520 Madison Avenue, 2nd Flooring, New York, NY 10022, by phone at (877) 821-7388 or by e-mail at prospectus—division@jefferies.com; SVB Leerink LLC, Consideration: Syndicate Division, One Federal Road, thirty seventh Flooring, Boston, MA 02110, by phone at (800) 808-7525, ext. 6105, or by e-mail at syndicate@svbleerink.com; or Guggenheim Securities, LLC Consideration: Fairness Syndicate Division, 330 Madison Avenue, New York, NY 10017 or by phone at (212) 518-9544, or by e mail at GSEquityProspectusDelivery@guggenheimpartners.com; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Flooring, New York, New York 10022 or by e mail at prospectus@cantor.com.

The providing might be made solely by the use of a prospectus. This press launch doesn’t represent a suggestion to promote or the solicitation of a suggestion to purchase any of the securities described herein, nor shall there be any sale of those securities in any state or different jurisdiction wherein such provide, solicitation or sale could be illegal previous to the registration or qualification beneath the securities legal guidelines of any such state or different jurisdiction.

About Celldex Therapeutics, Inc.

Celldex is a medical stage biotechnology firm devoted to growing monoclonal and bispecific antibodies that tackle devastating illnesses for which out there therapies are insufficient. Our pipeline contains antibody-based therapeutics which have the flexibility to have interaction the human immune system and/or instantly have an effect on crucial pathways to enhance the lives of sufferers with inflammatory illnesses and lots of types of most cancers.

Ahead Trying Assertion

This launch comprises “forward-looking statements” made pursuant to the secure harbor provisions of the Personal Securities Litigation Reform Act of 1995. These statements are usually preceded by phrases reminiscent of “believes,” “expects,” “anticipates,” “intends,” “will,” “might,” “ought to,” or related expressions. These forward-looking statements mirror administration’s present information, assumptions, judgment and expectations concerning future efficiency or occasions. Though administration believes that the expectations mirrored in such statements are affordable, they provide no assurance that such expectations will show to be right or that these objectives might be achieved, and try to be conscious that precise outcomes may differ materially from these contained within the forward-looking statements. Ahead-looking statements are topic to plenty of dangers and uncertainties, together with, however not restricted to, dangers related to market situations and the satisfaction of customary closing situations associated to the providing and uncertainties associated to the Firm’s expectations concerning the completion, timing and measurement of the providing. For an extra description of the dangers and uncertainties that might trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers regarding the Firm’s enterprise typically, please consult with the Firm’s prospectus complement to be filed with the SEC, and the paperwork included by reference therein, together with the Firm’s Type 10-Ok for the 12 months ended December 31, 2020 and Type 10-Q for the quarter ended March 31, 2021.

All forward-looking statements are expressly certified of their entirety by this cautionary discover. You’re cautioned to not place undue reliance on any forward-looking statements, which communicate solely as of the date of this launch. We have now no obligation, and expressly disclaim any obligation, to replace, revise or right any of the forward-looking statements, whether or not because of new info, future occasions or in any other case.

Firm Contact Sarah Cavanaugh Senior Vice President, Company Affairs & Administration Celldex Therapeutics, Inc. (508) 864-8337 scavanaugh@celldex.com

Patrick Until Senior Director, Investor Relations & Company Communications Celldex Therapeutics, Inc. (484) 788-8560 ptill@celldex.com  

Copyright 2021 GlobeNewswire, Inc.

https://www.djournal.com/celldex-therapeutics-announces-pricing-of-upsized-250-million-public-offering-of-common-stock/article_e7310a0d-6fd4-5a36-8f44-8fd63bec56f0.html

snopx

Inter Reviewed is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – admin@interreviewed.com. The content will be deleted within 24 hours.

Related Articles

Back to top button